Endocrine Disorders

In the 1980s, the lowest-observable-adverse effect-level (LOAEL) for BPA was determined at 50 mg/kgbw/day, and the Environmental Protection Agency (EPA) calculated a ‘‘reference dose’’ of 50 lg/kgbw. Since that time, abundant scientific evidence have suggested that BPA can interfere with the endocrine signaling pathways at doses below the calculated safe dose after fetal, neonatal, perinatal and adult exposure. Acting as an endocrine disruptor, BPA may interfere with endocrine transduction mechanisms at very low doses and the exposure to this contaminant has been correlated with a wide variety of adverse health effects in both male and female including birth defects, reproductive, developmental, metabolic, immune, and neurobehavioral disorders. Therefore, the effects exerted by BPA at low doses can be explained at least partially by the fact that this endocrine disruptor may bind differently than E2 within the ER ligand domain or recruit different ER co-activators. Marcello Maggiolini, Bisphenol-A: A Powerful Endocrine Disrupting Chemical

• Share this page
• 
• 
• 
• 
• 
• 

Last date updated on April, 2024